We are talking of mental health prevalence worsening but not addressing the fact that most people are now cry-babies.
Not to act cold but I have listened to many what people call depressing stories and it's just people raised softly.
Resigning from work just because your boss yells!! Really, people show up at workplaces without qualifications but just gumption.
Things aren't working out! Have you tried hawking? Or asked for a temporary job at a construction site?
I don't care that I have a degree, if I get broke, tomorrow you find me at a construction site trying to first fix lunch and supper as I apply for jobs early morning.
I have been around people who think I have no problems in life but listening to their stories and I'm like, "what!!, so you're stressed about that?, Isn't it part of life!" You literally keep putting one foot forward before you know it, you have everything your heart has ever wanted.
Where I come from, we are relentless. You put a wall before me, I will try going over it, around it, or dig under it. If I fail, I will just blow up the whole damn wall.
🚨Publication Alert
Another case report from Yumbe Regional Referral Hospital @Yumberrh
A Uro-obstetric emergency
🔗 https://t.co/ciRDXIsOvC
Internship in Yumbe was well spent 🤭
@mathie97@cosmas412@tomRoberto7@ivaan256
💊 DRUG OF THE DAY: Apixaban
Available adult tablet strengths: 2.5 mg and 5 mg.
Drug class: Direct oral anticoagulant (DOAC).
Apixaban is a selective, reversible, direct inhibitor of coagulation factor Xa.
It is indicated for stroke and systemic embolism prevention in nonvalvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent venous thromboembolism, and postoperative thromboprophylaxis following hip or knee replacement.
For acute DVT or PE, the recommended regimen is 10 mg twice daily for the first seven days, followed by 5 mg twice daily.
For extended prevention of recurrent DVT or PE, 2.5 mg twice daily is used after at least six months of initial anticoagulant treatment.
Pharmacokinetic Profile:
Oral bioavailability: 50%
Elimination half-life: 12 hours
Protein binding: 87%
Renal clearance: 27%
Metabolism: Primarily CYP3A4